Valneva SE 2023 SR
The report outlines Valneva's sustainability progress in 2023, focusing on four pillars: Protecting Lives, Acting Ethically, Developing People, and Respecting the Environment. Key highlights include the FDA approval of the chikungunya vaccine IXCHIQ and the creation of new ESG committees to oversee strategy. The company achieved 100% renewable electricity across its manufacturing and R&D sites and reduced its carbon footprint by 48% since 2019. Valneva also implemented a new governance structure, transitioning to a one-tier model with a Board of Directors.
Company: Valneva SE
Sector: Health Care
Country: France
Year: 2023
Type: SR
Pages: 48
Back to company
Valneva SE
Sustainability Report
The report outlines Valneva's sustainability progress in 2023, focusing on four pillars: Protecting Lives, Acting Ethically, Developing People, and Respecting the Environment. Key highlights include the FDA approval of the chikungunya vaccine IXCHIQ and the creation of new ESG committees to oversee strategy. The company achieved 100% renewable electricity across its manufacturing and R&D sites and reduced its carbon footprint by 48% since 2019. Valneva also implemented a new governance structure, transitioning to a one-tier model with a Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Mar 22, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees